In addition, Hui et al. [47] identified eight small molecule drugs targeting the protein HNRNPA2B1 and established a lncRNA–miRNA–mRNA (HNRNPA2B1) ceRNA network, which provides a new idea for clinical immunotherapy and the development of new therapeutic agents for bladder cancer. This evidence concerns the gene HNRNPA2B1 and urinary bladder cancer.